IGEV方案治疗复发难治性霍奇金淋巴瘤的临床研究 - Suppr

Suppr

超能文献

[A clinical study of IGEV regimen in the treatment of relapsed and refractory Hodgkin lymphoma].

作者信息

Tang Y, Wang X T, Li Y Y, Bai O, Gao S J, Liu C S

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):688-690. doi: 10.3760/cma.j.issn.0253-2727.2018.08.017.

DOI:10.3760/cma.j.issn.0253-2727.2018.08.017

PMID:30180475

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342832/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c5/7342832/eb220495502e/cjh-39-08-688-g001.jpg

相似文献

[A clinical study of IGEV regimen in the treatment of relapsed and refractory Hodgkin lymphoma].

Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):688-690. doi: 10.3760/cma.j.issn.0253-2727.2018.08.017.

Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.

Biol Blood Marrow Transplant. 2005 Sep;11(9):688-97. doi: 10.1016/j.bbmt.2005.05.014.

[Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].

Zhonghua Xue Ye Xue Za Zhi. 2015 Jul;36(7):578-82. doi: 10.3760/cma.j.issn.0253-2727.2015.07.011.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Ai Zheng. 2005 Apr;24(4):465-9.

[Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma].

Zhonghua Xue Ye Xue Za Zhi. 2013 Oct;34(10):857-61. doi: 10.3760/cma.j.issn.0253-2727.2013.10.007.

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.

Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.

Pharmacol Rep. 2019 Jun;71(3):473-477. doi: 10.1016/j.pharep.2019.02.001. Epub 2019 Feb 6.

Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.

J BUON. 2019 Nov-Dec;24(6):2483-2489.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.

Leuk Res. 2013 Sep;37(9):1178-83. doi: 10.1016/j.leukres.2013.03.021. Epub 2013 May 21.

本文引用的文献

Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.

Br J Haematol. 2019 Mar;184(5):840-844. doi: 10.1111/bjh.15186. Epub 2018 Mar 13.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.

Rapidly Progressing Refractory Hodgkin Lymphoma: A Case Report and a Possible Explanation.

Case Rep Med. 2016;2016:7698624. doi: 10.1155/2016/7698624. Epub 2016 Jun 26.

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15.

Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.

Leuk Res. 2009 Sep;33(9):e170-2. doi: 10.1016/j.leukres.2009.03.036. Epub 2009 Apr 28.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

Ann Oncol. 2008 Jul;19(7):1312-1319. doi: 10.1093/annonc/mdn052. Epub 2008 Mar 19.

Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients.

Blood. 2008 Mar 15;111(6):2977-83. doi: 10.1182/blood-2007-10-115493. Epub 2007 Dec 20.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Ann Oncol. 2007 Jun;18(6):1071-9. doi: 10.1093/annonc/mdm090. Epub 2007 Apr 10.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Haematologica. 2007 Jan;92(1):35-41. doi: 10.3324/haematol.10661.

ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.

Bone Marrow Transplant. 2006 Feb;37(3):277-82. doi: 10.1038/sj.bmt.1705239.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验